Prosecution Insights
Prosecution Insights
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.1% | -11.6% |
| PECKHAM, RICHARD GRANT | 1 | 67.2% | +37.0% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.8% |
| VARADARAJ, ARCHANA | 1 | 100.0% | +0.0% |
| REILLY, SOPHIA JANE | 1 | 60.6% | +49.1% |
| WESTERBERG, NISSA M | 1 | 23.3% | +36.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854489 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801057 | PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE AND SODIUM BICARBONATE HAVING EXCELLENT RELEASE PROPERTIES | WESTERBERG, NISSA M | 79d overdue |
| 18010399 | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | VARADARAJ, ARCHANA | 33d |
| 18039958 | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING GASTRITIS OR PEPTIC ULCER COMPRISING EXTRACT OF CINNAMOMUM CASSIA, FRACTION OF SAID EXTRACT, ISOLATE OF SAID FRACTION OR COMPOUNDS ISOLATED THEREFROM | BAEK, BONG-SOOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801057 | PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE AND SODIUM BICARBONATE HAVING EXCELLENT RELEASE PROPERTIES | WESTERBERG, NISSA M | 79d overdue |
| 17995947 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | REILLY, SOPHIA JANE | 5d overdue |
| 18686193 | COMPOSITIONS FOR PREVENTING OR TREATING CHARCOT-MARIE-TOOTH DISEASE (CMT) | PECKHAM, RICHARD GRANT | — |
| 18039958 | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING GASTRITIS OR PEPTIC ULCER COMPRISING EXTRACT OF CINNAMOMUM CASSIA, FRACTION OF SAID EXTRACT, ISOLATE OF SAID FRACTION OR COMPOUNDS ISOLATED THEREFROM | BAEK, BONG-SOOK | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1611 | 1 |
| 1658 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18854489 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | WARD, PAUL V | — | §112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18686193 | COMPOSITIONS FOR PREVENTING OR TREATING CHARCOT-MARIE-TOOTH DISEASE (CMT) | PECKHAM, RICHARD GRANT | 1627 | §102§103DP | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18039958 | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING GASTRITIS OR PEPTIC ULCER COMPRISING EXTRACT OF CINNAMOMUM CASSIA, FRACTION OF SAID EXTRACT, ISOLATE OF SAID FRACTION OR COMPOUNDS ISOLATED THEREFROM | BAEK, BONG-SOOK | 1611 | §102§103 | Final Rejection | — | Pending | Jun 01, 2023 |
| 18010399 | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | VARADARAJ, ARCHANA | 1658 | §102§103Other | Non-Final OA | 33d | Pending | Dec 14, 2022 |
| 17995947 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | REILLY, SOPHIA JANE | 1627 | §103Other | Non-Final OA | 5d overdue | Pending | Oct 11, 2022 |
| 17801057 | PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE AND SODIUM BICARBONATE HAVING EXCELLENT RELEASE PROPERTIES | WESTERBERG, NISSA M | 1618 | §103§112Other | Final Rejection | 79d overdue | Pending | Aug 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial